InMed Pharmaceuticals Inc. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from 2020 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
InMed Pharmaceuticals Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2020 to 2022.
  • InMed Pharmaceuticals Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending March 31, 2023 was -$2M, a 42.5% increase year-over-year.
  • InMed Pharmaceuticals Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending March 31, 2023 was -$15.5M, a 10.7% decline year-over-year.
  • InMed Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$18.6M, a 90.3% decline from 2021.
  • InMed Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$9.77M, a 4.42% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$18.6M -$8.83M -90.3% Jul 1, 2021 Jun 30, 2022 10-K 2022-09-23
2021 -$9.77M -$414K -4.42% Jul 1, 2020 Jun 30, 2021 10-K 2022-09-23
2020 -$9.36M Jul 1, 2019 Jun 30, 2020 10-K 2021-09-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.